Last updated: March 20, 2026
What is NDC 72305-0175?
The drug with NDC 72305-0175 is Sovaldi (sofosbuvir), manufactured by Gilead Sciences. It’s indicated for chronic hepatitis C virus (HCV) infection, covering various genotypes and typically prescribed in combination with other antivirals.
Market Overview
Market Size and Demand
The global hepatitis C market is projected to reach approximately USD 8.1 billion by 2027, growing at a compound annual growth rate (CAGR) of around 17.9% (ResearchandMarkets, 2022). Sovaldi was a market leader during its initial launch, commanding high prices before increasing generic competition.
Key Market Drivers
- Increasing awareness of HCV, leading to higher diagnosis rates.
- Expanding treatment guidelines endorsing direct-acting antivirals (DAAs).
- Improvements in cure rates surpass 95%.
Competitive Landscape
Sovaldi's main competitors include Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and generic versions of sofosbuvir available in some markets.
Patent and Exclusivity
Gilead held key patents until 2025, although some generic versions emerged earlier in certain jurisdictions due to legal challenges and licensing agreements.
Current Pricing
U.S. Pricing
- Brand-name Sovaldi: List price approximately USD 84,000 for a 12-week course.
- Average Medicaid and insurance reimbursements: USD 26,000–USD 30,000 per course.
- Per pill cost: Approximately USD 1,000–USD 1,500.
International Variations
- European prices average USD 55,000 to USD 65,000 per treatment course.
- Emerging markets exhibit significantly lower prices, often USD 10,000–USD 20,000, supported by licensing agreements.
Price Trends and Projections
Past Trends
Post-launch in 2013, the price of Sovaldi declined gradually due to generic entries and policy interventions. In 2017, Gilead reduced prices in some markets, and other manufacturers entered the space, exerting more downward pressure.
Future Projections (2023–2027)
| Year |
Estimated Average Price per Treatment Course |
Key Factors Influencing Price |
| 2023 |
USD 25,000 – USD 30,000 |
Increased generic approvals, insurance negotiations |
| 2024 |
USD 20,000 – USD 25,000 |
Continued generic proliferation, patent expiries |
| 2025 |
USD 15,000 – USD 20,000 |
Patent expiration in key markets; expanded licensing |
| 2026 |
USD 12,000 – USD 18,000 |
Market saturation, further compaction of pricing |
| 2027 |
USD 10,000 – USD 15,000 |
Wide generic access, licensing agreements |
Influential Factors
- Patent expiration drives a sharp drop in prices across markets.
- Patent challenges and legal actions can accelerate generic entry.
- Government and insurer negotiations aim to reduce costs further.
- New therapies entering the market may further erode prices.
Commercialization Challenges and Opportunities
Challenges
- Patent litigation delays generic competition.
- Pricing pressures in developed markets.
- Variability in treatment guidelines and eligibility.
- Limited access in low-income markets due to high prices.
Opportunities
- Expansion into underserved markets through licensing.
- Combination therapies reducing treatment duration and costs.
- New formulations offering improved adherence.
Key Takeaways
- NDC 72305-0175 (Sovaldi) experienced high initial prices, with market pressures prompting reductions.
- Projected average prices per treatment course decline steadily through 2027, reaching USD 10,000–USD 15,000.
- Patent expirations and generic competition are primary drivers of price erosion.
- Market growth remains robust due to high cure rates and expanded treatment coverage.
- Pricing strategies increasingly focus on licensing, formulary negotiations, and access programs.
FAQs
Q1: How does patent expiration affect the price of NDC 72305-0175?
Patent expiration in key markets leads to generic versions entering the market, causing prices to drop significantly due to increased competition.
Q2: Are there regional differences in the pricing of Sovaldi?
Yes. Developed countries like the U.S. and European nations maintain higher prices, while emerging markets see lower costs driven by licensing agreements and cost-control policies.
Q3: How have policy changes impacted the market?
Pricing negotiations, formulary restrictions, and government procurement programs have contributed to reducing overall drug costs.
Q4: What role will new HCV treatments play in future pricing?
New therapies can further increase competition, especially if they demonstrate comparable or superior efficacy with shorter treatment durations, pressuring Sovaldi prices downward.
Q5: Is there potential for price stabilization?
Prices are expected to stabilize at lower levels as patent protections lapse fully and generic options dominate, with access programs potentially maintaining higher prices in some contexts.
References
- ResearchandMarkets. (2022). Hepatitis C Virus (HCV) Market - Global Forecast to 2027.
- Gilead Sciences. (2023). Sovaldi (sofosbuvir) product monograph.
- IQVIA. (2022). Global Trends in Hepatitis C Treatment Prices.
- World Health Organization. (2021). Hepatitis C: Global health sector strategy on viral hepatitis.
- U.S. Food and Drug Administration. (2022). Patent and Exclusivity Data for Gilead’s Hepatitis C Products.
